MARKET

AGIO

AGIO

Agios Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.08
+0.91
+4.11%
Opening 11:08 07/01 EDT
OPEN
22.17
PREV CLOSE
22.17
HIGH
23.08
LOW
21.94
VOLUME
75.20K
TURNOVER
1.23M
52 WEEK HIGH
58.61
52 WEEK LOW
16.75
MARKET CAP
1.26B
P/E (TTM)
-3.6142
1D
5D
1M
3M
1Y
5Y
BRIEF-Centogene, Agios Expand Partnership For Clinical Development Of Pyrukynd (Mitapivat) To Treat Children With Rare Blood Disease
reuters.com · 06/13 10:36
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic te...
GlobeNewswire · 06/13 10:30
Centogene Expands Pyrukynd Development Partnership With Agios to Treat Children With Rare Blood Disease
MT Newswires · 06/13 07:04
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
– Treatment with PYRUKYND® Associated with Early and Robust Hemoglobin Responses in Phase 3 ACTIVATE and Extension Studies; Approximately One-Third of Patients Achieved Normal Hemoglobin Levels at Least Once – – PYRUKYND®-Treated Patients Reported Signific...
GlobeNewswire · 06/10 14:30
Goldman Sachs Adjusts Agios Pharmaceuticals' Price Target to $16 from $20, Keeps Sell Rating
MT Newswires · 05/24 10:46
Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff
Benzinga · 05/17 16:13
7 Analysts Have This to Say About Agios Pharmaceuticals
Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter:
Benzinga · 05/17 13:12
SVB Securities Adjusts Price Target for Agios Pharmaceuticals to $33 From $30, Maintains Market Perform Rating
MT Newswires · 05/17 11:38
More
No Data
Learn about the latest financial forecast of AGIO. Analyze the recent business situations of Agios Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

22.22%Strong Buy
22.22%Buy
44.44%Hold
11.11%Under-perform
0.00%Sell
Analyst Price Target
The average AGIO stock price target is 35.80 with a high estimate of 47.00 and a low estimate of 16.00.
High47.00
Average35.80
Low16.00
Current 23.17
EPS
Actual
Estimate
-1.45-1.09-0.72-0.36
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 254
Institutional Holdings: 64.43M
% Owned: 117.59%
Shares Outstanding: 54.79M
TypeInstitutionsShares
Increased
45
2.28M
New
22
590.65K
Decreased
57
2.22M
Sold Out
21
298.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.52%
Pharmaceuticals & Medical Research
+0.55%
Key Executives
Chairman/Director
David Schenkein
Chief Executive Officer/Director
Jacqualyn Fouse
Chief Financial Officer
Jonathan Biller
Chief Accounting Officer
T. J. Washburn
Chief Scientific Officer
Bruce Car
Other
James Burns
Other
Sarah Gheuens
Other
Richa Poddar
Lead Director/Independent Director
John Maraganore
Independent Director
Paul Clancy
Independent Director
Kaye Foster
Independent Director
Maykin Ho
Independent Director
David Scadden
No Data
No Data
About AGIO
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.

Webull offers kinds of Agios Pharmaceuticals Inc stock information, including NASDAQ:AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.